Key result
Warfarin therapy duration after bioprosthetic aortic valve replacement is associated with the risk of mortality, thromboembolic complications, and bleeding.
Why the study?
Does warfarin therapy duration affect the risk of mortality, thromboembolic complications, and bleeding in patients after bioprosthetic aortic valve replacement?
Does warfarin therapy duration affect the risk of mortality, thromboembolic complications, and bleeding in patients after bioprosthetic aortic valve replacement?
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mérie et al. (2013) studied this question. Warfarin therapy duration after bioprosthetic aortic valve replacement is associated with the risk of mortality, thromboembolic complications, and bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: